Real world study in Locally Advanced or Metastatic NSCLC patients, Progressed From First-line EGFR-TKI Therapy

Trial Identifier: D5160R00031
Sponsor:AstraZeneca
NCTID:NCT04207775
Start Date:March 2020
Primary Completion Date: March 2023
Study Completion Date: March 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

CountryLocation
China Beijing, China, 101149
China Beijing, China
China Changsha, China, 410013
China Chengdu, China, 610041
China Chengdu, China, 610042
China Guangzhou, China, 510080
China Guangzhou, China, 510630
China Hangzhou, China, 310022
China Hangzhou, China
China Harbin, China, 150081
China Hohhot, China, 010017
China Qingdao, China, 266042
China Shanghai, China
China Shenyang, China, 110044
China Suzhou, China, 215000
China Tai'an, China
China Taizhou, China, 317000
China Weihai, China
China Xi'an, China, 710004
China Xi'an, China, 710032
China Zhuji, China